Since its establishment, I-Mab has been focusing on developing innovative biologics in immuno-oncology. Through three waves of innovation, we have built a globally competitive pipeline. Our global clinical development and strategic partnership model fuels our sustainable innovation and growth, with proven track record of validation and recognition.